Adrian Bunta
Family · Litchfield Park, AZNPI 1043542061
Payments from drug & device makers
Across 1,108 payments — averaging $53.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$35K
- Otsuka America Pharmaceutical, Inc.$3K
- AbbVie$3K
- UCB, Inc.$2K
- Lilly USA, LLC$1K
- Amneal Pharmaceuticals LLC$936
- plus $13K from 54 others
What the payments were for
- Consulting fees$1,1302%
- Speaking & faculty fees$30,88052%
- Travel & lodging$3,3236%
- Food & beverage$22,90139%
- Education$6731%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$58,907 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 20 | $191,559 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 33 | $185,956 |
| Nurtec OdtRimegepant Sulfate | 49 | $84,924 |
| RexultiBrexpiprazole | 43 | $64,286 |
| XcopriCenobamate | 32 | $44,819 |
| UbrelvyUbrogepant | 30 | $43,898 |
| RytaryCarbidopa/Levodopa | 45 | $37,795 |
| Aimovig AutoinjectorErenumab-Aooe | 31 | $34,094 |
| BotoxOnabotulinumtoxina | 19 | $24,905 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 33 | $24,580 |
| Emgality PenGalcanezumab-Gnlm | 30 | $20,839 |
| Memantine Hcl | 570 | $19,504 |
| ElyxybCelecoxib | 20 | $16,631 |
| QuliptaAtogepant | 15 | $15,510 |
| Galantamine Hbr | 133 | $11,611 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $35,415 | $191,55920 claims |
| Grifols USA, LLCGamunex-C | $15 | $185,95633 claims |
| PfizerNurtec Odt | $557 | $84,92449 claims |
| AbbVieUbrelvy, Botox, Qulipta | $2,852 | $84,31364 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $3,310 | $64,28643 claims |
| SK Life Science, Inc.Xcopri | $686 | $44,81932 claims |
| Amneal Pharmaceuticals LLCRytary | $936 | $37,79545 claims |
| Scilex Pharmaceuticals Inc.Elyxyb | $199 | $16,63120 claims |
| Lilly USA, LLCReyvow | $1,044 | $8,16611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.
Other family in Litchfield Park
- Sharon MagalonaMesa$449K
- Angela GoldenMunds Park$378K
- Kimberly HallaPhoenix$332K
- Kaitlyn LouchheimScottsdale$208K
- Rebecca McCollaumMesa$149K
- Susan SarabiaSun City West$114K
- Lindsay CarterTucson$108K
- Audrey StevensonPhoenix$83K
- Keith MorsePrescott$83K
- Celeste FineGilbert$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.